As ESMO data raise doubts about PRAME target, Immunocore also looks to KRAS

Underwhelming initial data from the first-in-human study of Immunocore’s IMC-F106C have raised investor doubts about PRAME’s potential as a solid tumor antigen, particularly as a target for TCR bispecifics.

Shares of Immunocore Holdings plc (NASDAQ:IMCR) fell $12.75 (22%) to $44.74 last Friday after the company presented full interim data from a Phase I study of IMC-F106C, a TCR bispecific targeting PRAME, at the European Society of Medical Oncology (ESMO) Congress. The stock has continued to slide, finishing Tuesday’s session down 30% from last Thursday’s close...